Related Experiment Video

Updated: Aug 15, 2026

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
09:15

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Published on: November 10, 2017

Is aggressive lipid-lowering effective and safe in the older adult?

John C LaRosa1

  • 1State University of New York Downstate Medical Center, Brooklyn, NY 11203, USA. john.larosa@downstate.edu

Clinical Cardiology
|October 28, 2005
PubMed

Insights

Elderly patients benefit significantly from statin therapy for cardiovascular disease prevention. Despite proven safety and efficacy, statins are under-prescribed in this growing population, highlighting a gap in geriatric cardiovascular care.

Area of Science:

  • Geriatrics
  • Cardiovascular Medicine
  • Pharmacology

Background:

  • The elderly population is rapidly expanding in the U.S.
  • Cardiovascular disease (CVD) is a major cause of morbidity in older adults.
  • CVD poses a significant burden on patients and healthcare systems.

Purpose of the Study:

  • To review the benefits of HMG-CoA reductase inhibitor (statin) therapy in the elderly.
  • To discuss the perceived versus actual risks of statin use in older individuals.
  • To provide guidance on patient selection and risk minimization for statin therapy in geriatrics.

Main Methods:

  • Review of large, randomized, placebo-controlled trials on statin therapy in elderly populations.
  • Analysis of data regarding the safety and efficacy of statins in older adults.
  • Discussion of clinical guidelines and evidence-based practices for statin use in geriatrics.

Main Results:

  • Elderly patients demonstrate clear benefits from statin therapy in preventing or delaying disease progression and vascular events.
  • Aggressive statin therapy is generally safe and well-tolerated in the elderly population.
  • Despite evidence, statins are under-utilized in older individuals.

Conclusions:

  • Statin therapy is a safe and effective intervention for cardiovascular risk reduction in the elderly.
  • Addressing the under-prescription of statins requires better understanding of risk-benefit profiles and patient selection.
  • Further efforts are needed to optimize the use of statins in geriatric cardiovascular disease management.

Related Concept Videos

Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Metabolism01:18

Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Metabolism

Geriatric patients show significant variation in how their bodies process medications, which can change how effective and safe treatments are. The liver is the primary organ where drug metabolism occurs, involving two main types of chemical reactions: phase I and II. Phase I metabolism is driven by the cytochrome P450 enzyme system, which includes key types such as CYP3A, CYP2D6, and CYP2C9. Research indicates that while aging doesn't notably alter the levels or activity of these enzymes, it...
Drug Dosing: Geriatric Patients01:15

Drug Dosing: Geriatric Patients

Elderly individuals encompass a diverse population with varying degrees of age-related physiological changes. Defining the elderly presents challenges, as the geriatric population is often arbitrarily categorized as individuals older than 65. However, many individuals in this group lead active and healthy lives, with an increasing number surpassing 85 years and falling into the older elderly category. Physiological changes associated with aging impact performance capacity and homeostatic...
Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Distribution01:00

Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Distribution

Drug distribution in the human body is influenced by several factors, including plasma protein concentration, body composition, blood flow, tissue-protein concentration, and tissue fluid pH. Among these, changes in plasma protein concentration and body composition due to aging significantly affect how drugs are distributed within the body. Specifically, aging is associated with a decrease in albumin levels by about 10% and an increase in α1-acid glycoprotein levels. These alterations are not...
Pharmacodynamics in Geriatric Patients: Effects of Age01:27

Pharmacodynamics in Geriatric Patients: Effects of Age

Age-related pharmacokinetic changes are extensively documented, but understanding age-related pharmacodynamic alterations is relatively limited. This knowledge gap can be partly attributed to the complexity of developing appropriate measures of drug responses compared to bioanalytical methods for determining drug concentrations.Most information regarding age-related differences in human pharmacodynamics originates from cross-sectional studies. However, these studies assume that observed mean...